首页> 外文期刊>Hepatology: Official Journal of the American Association for the Study of Liver Diseases >Imaging mass spectrometry reveals modified forms of histone H4 as new biomarkers of microvascular invasion in hepatocellular carcinomas
【24h】

Imaging mass spectrometry reveals modified forms of histone H4 as new biomarkers of microvascular invasion in hepatocellular carcinomas

机译:成像质谱分析揭示了组蛋白H4的修饰形式,作为肝细胞癌微血管侵犯的新生物标志物

获取原文
获取原文并翻译 | 示例
           

摘要

Microvascular invasion (MiVI) is a major risk factor in postoperative tumor recurrence and mortality in hepatocellular carcinoma (HCC). Unfortunately, this histological feature is usually missed by liver biopsy because of limited sampling, and MiVI is commonly detected only after surgery and examination of the full resected specimen. To date, there exists no reliable tool for identifying MiVI prior to surgical procedures. This study aimed to compare the proteome of HCC with and without MiVI in order to identify surrogate biomarkers of MiVI. A training cohort comprising surgically resected primary HCC with MiVI (n=30) and without MiVI (n=26) was subjected to matrix-assisted laser desorption ionization imaging mass spectrometry (MALDI IMS). Comparative analysis of acquired mass spectra of the two groups yielded 30 differential protein peaks, among which 28 were more strongly expressed in HCC with MiVI. Among these, two peaks were identified as N-term acetylated histone H4 dimethylated at lysine (K) 20, and N-term acetylated histone H4 dimethylated at K20 and acetylated at K16. Both peaks were validated in the training cohort and in an independent validation cohort (n=23) by immunohistochemistry and western blot. Conclusion: These results demonstrate the potential of MALDI IMS for uncovering new relevant biomarkers of MiVI in HCC, and highlight the role of epigenetic modifications in the prognosis of HCC. Preoperative detection of modified forms of histone H4 expression in tumor biopsies would be helpful in management of patients with HCC.
机译:微血管浸润(MiVI)是肝细胞癌(HCC)术后肿瘤复发和死亡的主要危险因素。不幸的是,由于有限的采样,肝脏活检通常会错过这种组织学特征,并且通常只有在手术和检查完整切除的标本之后才能发现MiVI。迄今为止,尚无可靠的工具可在手术之前识别MiVI。这项研究旨在比较有或没有MiVI的HCC蛋白质组,以鉴定MiVI的替代生物标志物。对包含手术切除的原发性HCC且具有MiVI(n = 30)和不具有MiVI(n = 26)的训练队列进行基质辅助激光解吸电离成像质谱(MALDI IMS)。两组获得的质谱图的比较分析产生了30个差异蛋白峰,其中28个蛋白在带有MiVI的HCC中表达更强。其中,两个峰被鉴定为在赖氨酸(K)20处被二甲基化的N末端乙酰化组蛋白H4,在K20处被二甲基化并在K16处乙酰化的N末端乙酰化组蛋白H4。通过免疫组织化学和蛋白质印迹,两个峰均在训练队列和独立验证队列(n = 23)中进行了验证。结论:这些结果证明了MALDI IMS在揭示肝癌中MiVI新的相关生物标志物方面的潜力,并强调了表观遗传修饰在肝癌预后中的作用。术前在肿瘤活检中检测修饰形式的组蛋白H4表达将有助于肝癌患者的治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号